Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 10/20 | 0.49 |
| ▸ | REN | P00797 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | PEPD | P12955 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 1/20 | 0.49 |
| ▸ | THPO | P40225 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5013232 | 1.00 | ACE (0.49) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL3931067 | 1.00 | ACE (0.49) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL2177826 | 0.85 | ACE (0.51) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL2177815 | 0.85 | ACE (0.51) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL9166405 | 0.81 | ACE (0.49) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL14215476 | 0.81 | ACE (0.40) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL21081655 | 0.81 | FKBP1A (0.54) | LMNAPEPDRAB9A | |
| N-Acetylproline SCHEMBL428477 | 0.80 | ACE (0.54) | ACERENLMNAHSD17B10CYP2C19 | |
| N-Acetylproline SCHEMBL428476 | 0.80 | ACE (0.54) | ACERENLMNAHSD17B10CYP2C19 | |
| N-Acetylproline SCHEMBL358379 | 0.80 | ACE (0.54) | ACERENLMNAHSD17B10CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 466 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110156584-B | Synthesis method of (2R) -3-bromo-2-hydroxy-2-methylpropanoic acid | 长春金赛药业有限责任公司 | 2023-04-07 | — | — | CN | claimed |
| CN-101863806-B | Preparation method of medicine (R)-Bicalutamide for resisting prostatic cancer | HEBEI PROVINCE PHARMACEUTICAL INDUSTRY RES INST CO LTD | 2013-02-13 | — | — | CN | claimed |
| CN-101863806-A | Preparation method of medicine (R)-Bicalutamide for resisting prostatic cancer | HEBEI PROVINCE PHARMACEUTICAL INDUSTRY RES INST CO LTD | 2010-10-20 | — | — | CN | claimed |
| US-12215086-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-02-04 | — | — | US | disclosed |
| US-12202815-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-01-21 | — | — | US | disclosed |
| US-12128026-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2024-10-29 | — | — | US | disclosed |
| US-12115146-B2 | Treatment of skeletal-related events for breast cancer patients | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2024-10-15 | — | — | US | disclosed |
| US-20240326697-A1 | SOLID FORMS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2024-10-03 | — | — | US | disclosed |
| US-12053448-B2 | Solid forms of selective androgen receptor modulators | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2024-08-06 | — | — | US | disclosed |
| EP-3286164-B1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | ONCTERNAL THERAPEUTICS INC (US) | 2024-05-29 | — | — | EP | disclosed |
| US-11873282-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2024-01-16 | — | — | US | disclosed |
| US-20040014975-A1 | Synthesis of selective androgen receptor modulators | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, THE | 2004-01-22 | — | — | US | disclosed |
| US-20030232792-A1 | Selective androgen receptor modulators and methods of use thereof | TENNESSEE RESEARCH CORPORATION, THE UNIVERSITY OF | 2003-12-18 | — | — | US | disclosed |
| US-20030225040-A1 | Selective androgen receptor modulators and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2003-12-04 | — | — | US | disclosed |
| US-6569896-B2 | Useful for oral testosterone replacement therapy, male contraception, maintaining sexual desire in women, treating prostate cancer and imaging prostate cancer | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION | 2003-05-27 | — | — | US | disclosed |
| US-6492554-B2 | SUBSTITUTED ALPHA-HYDROXYISOBUTYRANILIDES; SUPPRESSING SPERMATOGENESIS; HORMONE THERAPY | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION | 2002-12-10 | — | — | US | disclosed |
| US-20020099036-A1 | Selective androgen receptor modulators and methods of use thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2002-07-25 | — | — | US | disclosed |
| US-20020099096-A1 | Selective androgen receptor modulators and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH CORPORATION, THE | 2002-07-25 | — | — | US | disclosed |
| US-4633025-A | INTERMEDIATES FOR SYNTHESIS OF PG ANALOGS | MILES LABORATORIES, INC. (US) | 1986-12-30 | — | — | US | disclosed |
| EP-0198352-A2 | Method for preparing (+)R-2-methyl-hexane-1,2-diol | MILES INC. (US) | 1986-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232792-A1 | Selective androgen receptor modulators and methods of use thereof | CYP19A1, AR, SHBG | ACE 1681/4885REN 3557/4885LMNA 1552/4885 |
| US-20030225040-A1 | Selective androgen receptor modulators and methods of use thereof | CYP19A1, SHBG, FSHR | ACE 1300/4885REN 2900/4885LMNA 1911/4885 |
| US-12115146-B2 | Treatment of skeletal-related events for breast cancer patients | AR, PGR, GNRHR | ACE 2579/4885REN 4306/4885LMNA 3380/4885 |
| US-20020099096-A1 | Selective androgen receptor modulators and methods of use thereof | AR, GNRHR, SHBG | ACE 2582/4885REN 2679/4885LMNA 3535/4885 |
| US-12215086-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, BRCA1, AHR | ACE 1850/4885REN 1730/4885LMNA 1024/4885 |
| US-12128026-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, AHR, BRDT | ACE 2199/4885REN 2209/4885LMNA 553/4885 |
| US-20020099036-A1 | Selective androgen receptor modulators and methods of use thereof | AR, SHBG, FSHR | ACE 1761/4885REN 1639/4885LMNA 4549/4885 |
| US-12053448-B2 | Solid forms of selective androgen receptor modulators | AR, FSHR, NR5A1 | ACE 1925/4885REN 953/4885LMNA 4198/4885 |
| US-11873282-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, AHR, BRDT | ACE 2199/4885REN 2209/4885LMNA 553/4885 |
| US-12202815-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, BRCA1, FSHR | ACE 1733/4885REN 2114/4885LMNA 723/4885 |
| US-20040014975-A1 | Synthesis of selective androgen receptor modulators | AR, CYP19A1, SHBG | ACE 1013/4885REN 2625/4885LMNA 1469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.